Global Industrial Trend and Market Demand Study on Peptic Ulcer Drugs: North America to Lead in During Forecast Period 2016 - 2022, Driven by Increasing NSAID Consumption
"Global
Market Study on Peptic Ulcer Drugs: North America to Lead in Global
Market During Forecast Period 2016 - 2022, Driven by Increasing NSAID
Consumption"
The Report covers current Industries Trends, Worldwide Analysis,
Global Forecast, Review, Share, Size, Growth, Effect.
Description-
Peptic
ulcer disease represents a group of ulcerative disorders such as
gastritis, gastric ulcers, and duodenal ulcers or gastroesophageal
reflux disease (GERD). Treatment of peptic ulcers is achieved through
drugs such as proton pump inhibitors (PPI), potassium-competitive
acid blockers (P-CAB), antacid, H2-antagonist, antibiotics, and ulcer
protective drugs such as sucralfate. Increasing usage of
non-steroidal anti-inflammatory drugs such as aspirin due to
increasing inflammatory conditions is the major factor driving the
growth of the global peptic ulcer drugs market. However, side effects
of long-term use of PPIs, changing government policies, loss of
market exclusivity of a majority of peptic ulcer drugs, and limited
R&D efforts in the field of peptic ulcer drugs are factors
expected to hamper the growth of peptic ulcer drugs market, globally.
Get
Sample
Report
With TOC @
http://www.researchmoz.us/enquiry.php?type=S&repid=1287192
The
peptic ulcer drugs market is segmented as follows:
By Product Type
By Disease Indication
By Distribution Channels
By Region
This report covers the global peptic ulcer drugs market performance in terms of revenue contribution. The report includes key trends, drivers, restraints, and opportunities influencing the growth of the global peptic ulcer drugs market over the forecast period. Impact analysis of key growth drivers and restraints, based on the weighted average model, are included to provide clients with crystal clear decision-making insights.
Based on product type, the global peptic ulcer drugs market is segmented into proton pump inhibitors (PPI), potassium-competitive acid blockers (P-CAB), antacids, ulcer protective drugs, H2-antagonists, and antibiotics. The PPIs segment is expected to remain the dominant segment in terms of value during the forecast period.
By disease indication, the global peptic ulcer drugs market is segmented as gastritis, gastric ulcer, duodenal ulcer or gastroesophageal reflux disease (GERD). GERD segment is expected to dominate in terms of market share contribution, accounting for the maximum share of the overall market by 2022 end; whereas revenue from gastric ulcer segment is projected to expand at highest CAGR of during the forecast period.
On the basis of the distribution channel, hospital pharmacies segment is expected to hold maximum market share in the global market for peptic ulcer drugs.
By region, the market in North America is expected to lead in the global peptic ulcer drugs market. In 2014, North America and Europe collectively accounted for 67% share of overall marker revenue. Asia Pacific market accounted for 22% share in global peptic ulcer drugs market and is expected to gain significant market share over the forecast period, due to increasing recurrence of peptic ulcer disease. The MEA market is expected to witness sluggish growth during the forecast period partly due to low accessibility to peptic ulcer drugs in the region.
Key segments covered
Product Type
Proton Pump Inhibitors (PPIs)
Potassium-Competitive Acid Blockers
Antacids
H2-antagonists
Antibiotics
Ulcer Protective Drugs
Disease Indication
Gastritis
Gastric Ulcer
Duodenal Ulcer
Gastroesophageal Reflux Disease (GERD)
Distribution Channel
Hospital Pharmacies
Private Clinics
Drug Stores
Retail Pharmacies
e-Commerce
Key Regions/Countries Covered
North America
U.S.
Canada
Europe
Germany
Italy
France
U.K.
Spain
Russia
Rest of Europe
Asia Pacific
China
India
Japan
Australia
South Korea
Rest of Asia Pacific
Latin America
Mexico
Brazil
Argentina
Rest of Latin America
MEA
GCC Countries
South Africa
Rest of MEA
Key features included in this report
Drivers and restraints of the peptic ulcer drugs market
Pipeline analysis and key developments in the market
Analysis of business strategies of key players
Peptic ulcer drugs market estimates and forecast
By Product Type
By Disease Indication
By Distribution Channels
By Region
This report covers the global peptic ulcer drugs market performance in terms of revenue contribution. The report includes key trends, drivers, restraints, and opportunities influencing the growth of the global peptic ulcer drugs market over the forecast period. Impact analysis of key growth drivers and restraints, based on the weighted average model, are included to provide clients with crystal clear decision-making insights.
Based on product type, the global peptic ulcer drugs market is segmented into proton pump inhibitors (PPI), potassium-competitive acid blockers (P-CAB), antacids, ulcer protective drugs, H2-antagonists, and antibiotics. The PPIs segment is expected to remain the dominant segment in terms of value during the forecast period.
By disease indication, the global peptic ulcer drugs market is segmented as gastritis, gastric ulcer, duodenal ulcer or gastroesophageal reflux disease (GERD). GERD segment is expected to dominate in terms of market share contribution, accounting for the maximum share of the overall market by 2022 end; whereas revenue from gastric ulcer segment is projected to expand at highest CAGR of during the forecast period.
On the basis of the distribution channel, hospital pharmacies segment is expected to hold maximum market share in the global market for peptic ulcer drugs.
By region, the market in North America is expected to lead in the global peptic ulcer drugs market. In 2014, North America and Europe collectively accounted for 67% share of overall marker revenue. Asia Pacific market accounted for 22% share in global peptic ulcer drugs market and is expected to gain significant market share over the forecast period, due to increasing recurrence of peptic ulcer disease. The MEA market is expected to witness sluggish growth during the forecast period partly due to low accessibility to peptic ulcer drugs in the region.
Key segments covered
Product Type
Proton Pump Inhibitors (PPIs)
Potassium-Competitive Acid Blockers
Antacids
H2-antagonists
Antibiotics
Ulcer Protective Drugs
Disease Indication
Gastritis
Gastric Ulcer
Duodenal Ulcer
Gastroesophageal Reflux Disease (GERD)
Distribution Channel
Hospital Pharmacies
Private Clinics
Drug Stores
Retail Pharmacies
e-Commerce
Key Regions/Countries Covered
North America
U.S.
Canada
Europe
Germany
Italy
France
U.K.
Spain
Russia
Rest of Europe
Asia Pacific
China
India
Japan
Australia
South Korea
Rest of Asia Pacific
Latin America
Mexico
Brazil
Argentina
Rest of Latin America
MEA
GCC Countries
South Africa
Rest of MEA
Key features included in this report
Drivers and restraints of the peptic ulcer drugs market
Pipeline analysis and key developments in the market
Analysis of business strategies of key players
Peptic ulcer drugs market estimates and forecast
Comments
Post a Comment